T cell receptor-therapy in HBV-related hepatocellularcarcinoma

Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a promising option for cancer treatment and could include hepatocellularcarcinoma (HCC), where therapeutic options are limited. We have recently investigated whether hepatitis B viral antigens can act as a HCC-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertoletti, Antonio, Brunetto, Maurizia, Maini, Mala K, Bonino, Ferruccio, Qasim, Waseem, Stauss, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485715/
https://www.ncbi.nlm.nih.gov/pubmed/26155416
http://dx.doi.org/10.1080/2162402X.2015.1008354
Descripción
Sumario:Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a promising option for cancer treatment and could include hepatocellularcarcinoma (HCC), where therapeutic options are limited. We have recently investigated whether hepatitis B viral antigens can act as a HCC-specific antigen and thus be targeted by adoptively transferred HBV-specific TCR redirected T cells.

Ejemplares similares